Reveals omitting axillary staging is noninferior to sentinel-lymph-node biopsy in node-negative breast cancer, indicating surgical lymph node removal may be safely omitted.
In this trial involving patients with clinically node-negative, T1 or T2 invasive breast cancer (90% with clinical T1 cancer and 79% with pathological T1 cancer), omission of surgical axillary staging was noninferior to sentinel-lymph-node biopsy after a median follow-up of 6 years. (Funded by the German Cancer Aid; INSEMA ClinicalTrials.gov number, NCT02466737.).
No takes yet. Share an insight, caveat, or question.
Reimer et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: